Sen. Bernie Sanders and Rep. Elijah Cummings request details after Ariad repeatedly raised the price of its drug. » Read More
Jefferies shares its favorite biotech stock ideas to pick up amid the recent share price weakness due to Hillary Clinton's rising poll numbers.
A cybersecurity expert explains to CNBC why a breach of a medical device maker could be a new front in the hacking wars.
Martin Shkreli's lawyers previously suggested that his defense would be based on the claim that he had been relying on the advice of his lawyer.
"Pharma bro" Martin Shkreli wanted to visit a Brooklyn bar immediately after his hearing in Brooklyn Friday afternoon, but one establishment put a stop to that.
Medicare ratings cuts at Humana may signal a higher bar for other Medicare insurers, an analyst says.
Humana fell Wednesday after a report by the Centers for Medicare and Medicaid Services showed its membership highly rated Medicare plans declined.
Federal health officials and the drug company Mylan are refusing to explain why full rebates for EpiPen are being delayed.
Illumina shares sink after the company trimmed its third-quarter revenue projections.
Zocdoc wants to make "Unsick Days" common, so workers can get checkups during a paid day off without having to worry about repercussions.
Shares of Bristol-Myers Squibb fell 10 percent, after the Opdivo trial result did not meet expectations.
Mylan soared Monday after it agreed to pay $465 million to settle charges that it overcharged the government for its EpiPen products.
After being largely ignored during the first presidential debate, the Affordable Care Act just got a lot of attention from Clinton and Trump.
Bristol-Myers Squibb's approach to treating lung cancer will have a chance to redeem itself when new data comes out on Sunday.
It's not clear when EpiPen owner Mylan was told by health officials it was misclassifying the anti-allergy device for rebate purposes.
Many hospitals in the path of the hurricane altered their operations.
Alnylam Pharmaceuticals said it would halt development of an experimental therapy for a rare genetic condition that can cause heart failure.
Get the best of CNBC in your inbox